Clinical Focus

  • Psychiatry

Academic Appointments

  • Clinical Professor, Psychiatry and Behavioral Sciences

Professional Education

  • Medical Education: Tulane University School of Medicine (1961) LA
  • Internship: Mount Sinai Medical Center (1962) NY
  • Residency: Stanford University School of Medicine (1965) CA
  • Fellowship: Stanford University School of Medicine (1964) CA
  • Residency: Perelman School of Medicine University of Pennsylvania (1968) PA
  • Board Certification: American Board of Psychiatry and Neurology, Psychiatry (1975)

Contact

  • Academic
    alringold@sbcglobal.net
    University - Staff Department: Psych/General Psychiatry and Psychology (Adult) Position: Clinical Professor
    • PBS C305
    • Stanford,  California  94305-5717 
    University - Affiliate Department: Psychiatry and Behavioral Sciences
  • Clinical (Primary)  Psychiatry Clinic 401 Quarry Rd Rm 2303 Stanford, CA 94305 (650) 724-9900 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5717

2024-25 Courses

All Publications

  • Efficacy of Ketamine in Unmedicated Adults With Obsessive-Compulsive Disorder: A Randomized Controlled Trial Rodriguez, C., Chen, C., Glover, G., Jo, B., Spielman, D., Williams, L., van Roessel, P., DeBattista, C., Flood, P., Ringold, A., Wintermark, M., Anderson, K., Linkovski, O., Lombardi, A., Millen, A., Pinto, A., Raila, H., Valentine, K., Filippou-Frye, M., Hawkins, J., McCarthy, E., Mukunda, P., Varias, A., Wilson, J., Wright, B. SPRINGERNATURE. 2022: 302-303

    View details for Web of Science ID 000897934700574

  • Efficacy of Ketamine in Unmedicated Adults With Obsessive-Compulsive Disorder: A Randomized Controlled Trial Rodriguez, C., Chen, C., Glover, G., Jo, B., Spielman, D., Williams, L., Van Roessel, P., DeBattista, C., Flood, P., Ringold, A., Wintermark, M., Anderson, K., Linkovski, O., Lombardi, A., Millen, A., Pinto, A., Raila, H., Valentine, K., Filippou-Frye, M., Hawkins, J., McCarthy, E., Mukunda, P., Varias, A., Wilson, J., Wright, B. SPRINGERNATURE. 2022: 302-303

    View details for Web of Science ID 000929613800574

  • Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder JOURNAL OF CLINICAL PSYCHIATRY Koran, L. M., Ringold, A. L., Elliott, M. A. 2000; 61 (7): 514-517

    Abstract

    Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD). Since olanzapine and risperidone have similar serotonergic and dopaminergic receptor binding profiles, we tested the hypothesis that olanzapine augmentation would be beneficial in treatment-unresponsive OCD.For this 8-week trial, we recruited 10 adult OCD patients (DSM-IV criteria) unresponsive to fluoxetine (> or =60 mg/day) for > or =10 weeks, which was continued throughout the trial. Other psychotropic medications were discontinued. Subjects had OCD for > or =1 year, a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of > or =18, and no organic, psychotic, or other primary Axis I disorder. Two weeks after olanzapine, 2.5 mg/day, was added, and in the absence of responder status (Y-BOCS score decrease > or =25%) and limiting side effects, we increased the dose to 5 mg/day, and after 2 more weeks, to 10 mg/day for 4 weeks.The subjects had failed a mean of 3.3 SRI trials (range, 1-5) and had a mean +/- SD baseline Y-BOCS score of 29.0 +/- 4.9. Nine patients completed the trial. The subjects' mean +/- SD endpoint Y-BOCS score was 24.4 +/- 8.0 (a 16% decrease). The 3 responders' Y-BOCS scores dropped 68%, 30%, and 29%, but only 1 patient was rated "much improved." He maintained this improvement during a 6-month follow-up period taking olanzapine, 5 mg/day. Improvement in OCD was independent of improvement in mood symptoms. Six patients (60%) experienced significant weight gain.Olanzapine augmentation may benefit treatment-unresponsive OCD. Double-blind, placebo-controlled trials are warranted along with trials comparing risperidone and olanzapine augmentation.

    View details for Web of Science ID 000088589400009

    View details for PubMedID 10937610

  • FLUOXETINE FOR TRICHOTILLOMANIA - AN OPEN CLINICAL-TRIAL PSYCHOPHARMACOLOGY BULLETIN Koran, L. M., RINGOLD, A., Hewlett, W. 1992; 28 (2): 145-149

    Abstract

    Of 17 adult patients with long-standing trichotillomania, 13 completed an 8- to 12-week open trial of fluoxetine, up to 80 mg per day. No patient had obsessive-compulsive disorder or major depression. We used the compulsions subscale of the Yale-Brown Obsessive-Compulsive Scale (YBOCS) to rate patients' hair-pulling behavior. The 13 completing patients' mean YBOCS score decreased significantly from 10.15 at baseline to 5.92 at the completion visit (Student's paired t = 4.82, df = 12, two-tailed p less than .001). Of these 13 patients, 5 experienced a 50 percent or greater decrease in their pulling behavior as measured by the YBOCS; 4 experienced between a 25 percent and 50 percent decrease. Three of the patients stopped pulling entirely, as did 2 of the 4 noncompleting patients. Three noncompleting patients discontinued treatment because of side effects, and 1 insisted on early use of behavior therapy. Comparative treatment trials elucidating the indications, risks, and expectable benefits of psychotherapeutic and pharmacological treatments are needed.

    View details for Web of Science ID A1992JG20100005

    View details for PubMedID 1513916

  • EMOTIONAL ANTECEDENTS OF BLEEDING FROM PEPTIC ULCER PSYCHIATRY IN MEDICINE HOLLENDE, M. H., Soults, F. B., Ringold, A. L. 1971; 2 (3): 199-204

    View details for Web of Science ID A1971K501300003

    View details for PubMedID 5148638